Doctor profile · Federal record
Dr. Tejvir Singh, M.D.
Hematology & Oncology Physician (CMS: Internal Medicine) · Specialist · Reno, NV
- NPI 1932139136
- Accepts Medicare
- MIPS 69.9 / 100 · 2023
- 40 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
5423 Reno Corporate Dr.
Reno, NV 895112250
(775) 329-0873
fax (775) 329-1026 - Mailing address
-
5423 Reno Corporate Dr
Reno, NV 895112250
Credentials & registration
- NPI registered
- July 2006 — 20 yrs on file
- Profile last updated
- November 3, 2020
- Year of graduation
- 1986 — 40 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Nevada #11877
- Medicaid
- IA #0291112
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1932139136. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
129,994
Distinct HCPCS
10
Medicare allowed
$3,152,653
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J9299 |
Injection, nivolumab, 1 mg | 20,480 | 12 | $30 | |
J9271 |
Injection, pembrolizumab, 1 mg | 18,200 | 26 | $54 | |
J0897 |
Injection, denosumab, 1 mg | 16,080 | 38 | $23 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 14,484 | 11 | $0 | |
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 12,750 | 13 | $0 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 10,620 | 16 | $48 | |
J0894 |
Injection, decitabine, 1 mg | 9,500 | 17 | $2 | |
J0185 |
Injection, aprepitant, 1 mg | 6,630 | 19 | $2 | |
J9041 |
Injection, bortezomib, 0.1 mg | 3,955 | 16 | $5 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 2,848 | 87 | $0 |
In context: peer comparison
Among 8 peers in this city , average services per provider: 1,102. This provider delivers 118× the peer median.Open Payments
Industry payments received
All-time total
$7,086
Transactions
47
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen Inc. | 2 | $2,806.21 | |
| E.R. Squibb & Sons, L.L.C. | 5 | $1,520.11 | |
| AstraZeneca Pharmaceuticals LP | 7 | $1,495.03 | |
| Novartis Pharmaceuticals Corporation | 4 | $130.91 | |
| Daiichi Sankyo Inc. | 5 | $110.48 | |
| PFIZER INC. | 5 | $86.97 | |
| Janssen Biotech, Inc. | 2 | $74.44 | |
| Genentech USA, Inc. | 3 | $65.36 | |
| TerSera Therapeutics LLC | 2 | $65.06 | |
| SpringWorks Therapeutics, Inc. | 2 | $58.26 | |
| Astellas Pharma US Inc | 2 | $50.91 | |
| Mirati Therapeutics, Inc. | 2 | $49.99 | |
| ARRAY BIOPHARMA INC | 2 | $49.96 | |
| GlaxoSmithKline, LLC. | 2 | $49.33 | |
| Incyte Corporation | 2 | $48.68 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
741
Patients
183
Total drug cost
$969,535
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 119 | 37 | $2,746 |
| Eliquis (Apixaban) | Brand | 72 | 15 | $55,321 |
| Acyclovir | Generic | 69 | 18 | $1,180 |
| Alendronate Sodium | Generic | 57 | 14 | $869 |
| Prednisone | Generic | 57 | 16 | $517 |
| Abiraterone Acetate | Generic | 47 | 0 | $109,688 |
| Venclexta (Venetoclax) | Brand | 44 | 0 | $331,321 |
| Hydroxyurea | Generic | 43 | 13 | $2,190 |
| Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) | Brand | 40 | 21 | $763 |
| Imatinib Mesylate | Generic | 40 | 0 | $17,936 |
Hospital affiliations
Frequently asked questions
What is Dr. Tejvir Singh's medical specialty?
Dr. Tejvir Singh practices Hematology & Oncology Physician in Reno, NV.
Where does Dr. Tejvir Singh practice?
Dr. Tejvir Singh practices at 5423 Reno Corporate Dr., Reno, NV 895112250. Office phone: 7753290873.
What is Dr. Tejvir Singh's NPI?
Dr. Tejvir Singh's National Provider Identifier (NPI) is 1932139136, issued by NPPES.
Does Dr. Tejvir Singh accept Medicare assignment?
Yes. Dr. Tejvir Singh accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Tejvir Singh commonly perform?
Top Medicare-reported procedures in 2023: Injection, nivolumab, 1 mg (HCPCS J9299); Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, denosumab, 1 mg (HCPCS J0897). Source: CMS Medicare Physician & Other Practitioners file.